Metformin, amoxilin and other 55 drug price reduction unseeded varieties price linkage does not drop the network

the | In November, most provinces and cities across the country will use the third batch of national varieties after the price cut.
metformin, ibuprofen, amoxilin... At the end of this month, the third batch of national harvest results in August this year, the third batch of national mining in Shanghai, a total of 55 drugs were selected, an average price reduction of 53%, the highest decline of 95%.
including high blood pressure, diabetes, antibiotics and other commonly used drugs, the first-line sugar-lowering drug metformin, in the country has more than 5 billion yuan of large-scale market, in the third batch of countries on the opening day of the bid competition is extremely fierce.
In addition to metformin, omeprazole, ibuprofen, dopamine, finasteride, amoxicillin and more than 10 varieties reported a dime price, vitamin B6, katopuri, chlorine and nitrogen equal offer of a few cents.
, provinces and cities began to implement the third batch of national harvest results.
incomplete statistics, there are currently 28 provinces and cities clear landing implementation date, is expected to be able to use most parts of the country at the end of this month after the price reduction of the third batch of national varieties.
From the current implementation of the third batch of national harvest results, hydrochloric acid metformin tablets specifications of 0.5g x 60 tablets, the original hanging network price of 65.8 yuan per box, after the price reduction of each box is expected to reach 3.4 yuan; 51 yuan, the price after the price reduction of 16.48 yuan, a decrease of 89%; Menglust sodium chewing tablets from the original 81.14 yuan / box, reduced to 2.98 yuan / box, a drop of up to 96.3%; Prior to the original research drug companies in the third batch of national mining in a large number of abandonment of the bid caused concern, data show that a number of original research drugs almost monopolized the market, 38 original research drugs accounted for more than half of their respective areas of market share.
The original research drug enterprises to abandon the market, on the one hand may be in the maintenance of the global price system of drugs, on the other hand, the original research drug by virtue of the accumulation of word-of-mouth, brand effect over the years, but also in the market outside the collection, the off-site market channels become the place to win and fail to select products.
and because of the withdrawal of the original pharmaceutical companies, generic pharmaceutical companies can have more market space in the hospital, the past monopoly of the original drug will be gone forever.
Not selected product price linkage, "removal tide" attack for the selected products, especially the original market share is not high products, through this volume of procurement can better expand market share, and for the unseeded products, some places can also start to implement price linkage in the near future, and the enterprise quotation did not reach the established range will be cancelled hanging network, whether through consistent evaluation of the product in the price reduction "treatment" also has a great difference.
For example, Heilongjiang Province requires the third batch of non-selected pharmaceutical production enterprises to fill in the lowest prices in other provinces of the country (excluding the third batch of nationally selected prices); The minimum purchase price of a drug trading platform as its purchase price, the implementation of the province-wide price linkage, with the selected drugs with the generic name, the same dosage form, different specifications of non-selected drugs, the implementation of the voluntary principle of the enterprise price linkage, Sichuan Province: non-selected drugs and joint procurement of the formation of a gradient of price reduction results to maintain price linkage.
the differential price rule, all non-selected drugs are not higher than the Shanghai maximum price drug price reduction results.
non-selected drugs with different refined dosage forms, specifications and packaging of the selected drugs shall be adjusted according to the price difference of the selected drugs, and the prices of other non-selected drugs that have not passed the consistent evaluation shall not be higher than the price of the selected drugs.
Qinghai Province: the state centralized procurement of the selected drugs not selected as the supply area of Qinghai Province, to no higher than the selected price directly hung on the net; Unseeded drugs, not higher than the selection of Qinghai Province as the supply area of the selected drug prices directly hung on the net, with the generic name has not been evaluated the unestaished drugs to be lower than the selection of Qinghai Province as the supply area of the selected drug prices, and not higher than the unestactioned drugs and the national minimum procurement price directly hung online.
the same time, some places also require that the uneliged review has been full of three products, disqualifying the network.
For example, Sichuan Province mentioned that "belongs to the third batch of generic drugs, the same variety of drugs through the consistent evaluation of the production enterprises reached more than 3, the failure to pass the consistent evaluation of the online trading function temporarily closed, pending the adoption of the consistency evaluation of the relevant enterprises can be re-declared and opened."
", Qinghai Province pointed out that the same variety of drugs through the consistent evaluation of more than 3 (including 3), no longer through the consistent evaluation of generic drugs are not registered ... At present, the national collection of drugs has been carried out to the third batch, before the industry forecast the fourth batch at the end of the year or early next year, in the volume of procurement mechanism, the selected varieties, unseeded varieties, as well as not selected and failed to pass the consistent evaluation of the market share will be reshuffled, not selected unappre assessed varieties face the survival crisis.
the first two batches of collection and implementation, Sanofi, Beijing Jialin, Xinlitai and so on have been exposed to cut sales staff.
the current cold winter has come, a large number of pharmaceutical representatives due to changes in the sales environment will face elimination and transformation.
with the collection, consistent evaluation, medical insurance and other in-depth promotion, since this year, many pharmaceutical companies began to transform, layoffs, the wave of enterprise departures also reached a small peak.